Zimmer Biomet, a pioneer in making medical devices, is joining hands with Network18 to promote awareness about arthritis and bone health.
→ Google 번역
NEW YORK , Sept. 28, 2022 /PRNewswire/ -- The Insight Partners published latest research study on " Orthopedic Implants Market Size, Share, Revenue, Growth Strategy, Industry Trends and Forecast to 2028 - COVID-19 Impact and Global Analysis by Product, Application, End User, and Geography", the global orthopedic implants market size is expected to grow from $46.10 Billion in 2021 to $67.23 Billion by 2028; it is expected to grow at a CAGR of 5.6% from 2022 to 2028. Download Sample Brochure of Orthopedic Implants Market Size - COVID-19 Impact and Global Analysis with Strategic Insights at: https://www.theinsightpartners.com/sample/TIPRE00024316/ Orthopedic Implants Market Report Scope, Segmentations, Regional & Country Scope: Report Coverage Details Market Size Value in US$ 46.10 Billion in 2021 Market Size Value by US$ 67.23 Billion by 2028 Growth rate CAGR of 5.6% from 2022 to 2028 Forecast Period 2022-2028 Base Year 2021 No. of Pages 150 Historical data available Yes Segments covered Product, Application, End User, and Geography Regional scope North America; Europe; Asia Pacific; Latin America; MEA Country scope US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends Companies Covered DJO Finance LLC; Johnson & Johnson (DePuy Synthes); Medtronic Plc; Zimmer Biomet Holdings, Inc.; Stryker Corporation; NuVasive, Inc.; CONMED Corporation; Smith and Nephew Plc; Arthrex, Inc.; Globus Medical, Inc.
→ Google 번역
Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in shares of Zimmer Biomet Holdings, Inc. by 6.4% during the 2nd quarter, according to the company in its…
→ Google 번역
The U.S. Food and Drug Administration ((FDA)) granted 510(k) clearance to Zimmer Biomet''s (ZBH) Identity Shoulder System for anatomic, reverse and revision shoulder replacement. The…
→ Google 번역
WASHINGTON (dpa-AFX) - Medical technology firm Zimmer Biomet Holdings, Inc. (ZBH) announced Tuesday the U.S. Food and Drug Administration (FDA) 510(k) clearance of the Identity Shoulder System for…
→ Google 번역
WARSAW, Ind., Sept. 20, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Identity™ Shoulder System for anatomic, reverse and revision shoulder…
→ Google 번역
Zimmer Biomet seems to be more likely to form a sideways movement or continue in its downtrend. Click here to see why ZBH is a long-term laggard in its industry.
→ Google 번역
Zimmer Biomet (ZBH) Signs Co-Marketing Agreement for HipInsight Nasdaq
→ Google 번역
Zimmer Biomet Holdings found using ticker (ZBH) have now 20 analysts in total covering the stock. The consensus rating is ''Hold''. The range between the high target price and low target price is between 145 and 114 calculating the mean target price we have 127. Now with the previous closing price of 106.8 this would indicate that there is a potential upside of 18.9%. The 50 day moving average now sits at 109.21 and the 200 moving average now moves to 117.65. The market cap for the company is $22,151m. Find out more information at: https://www.zimmerbiomet.com [stock_market_widget type="chart" template="basic" color="green" assets="ZBH" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $26,340m based on the market concensus. Zimmer Biomet Holdings, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
→ Google 번역
Zimmer Biomet (ZBH) signed an exclusive, multi-year co-marketing agreement with Surgical Planning Associates to commercialize HipInsight, a mixed reality navigation system for total…
→ Google 번역
WARSAW, Ind., Sept. 1, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced an exclusive, multi-year co-marketing agreement with Surgical Planning Associates, Inc. to commercialize HipInsight™, the first FDA-cleared…
→ Google 번역
Zimmer Biomet Holdings with ticker code (ZBH) now have 20 analysts covering the stock with the consensus suggesting a rating of ''Hold''. The range between the high target price and low target price is between 145 and 114 calculating the mean target price we have 127. With the stocks previous close at 111.94 this would indicate that there is a potential upside of 13.5%. The 50 day moving average now sits at 108.94 while the 200 day moving average is 118.19. The company has a market cap of $22,558m. Find out more information at: https://www.zimmerbiomet.com [stock_market_widget type="chart" template="basic" color="green" assets="ZBH" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $25,593m based on the market concensus. Zimmer Biomet Holdings, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
→ Google 번역
Zimmer Biomet (ZBH) declares $0.24/share quarterly dividend, in line with previous.
→ Google 번역
WARSAW, Ind., Aug. 26, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2022. The cash…
→ Google 번역
WARSAW, Ind., Aug. 26, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2022. The cash…
→ Google 번역
Related Stocks: BAX , CVS , ZBH , MSFT , GOOGL ,
→ Google 번역
Related Stocks: GILD , BDX , PFE , ALNY , ZBH ,
→ Google 번역
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX ) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume. ECMOHO Limited (NASDAQ: MOHO ) jumped 146.1% to settle at $0.4085 on above-average volume. Helius Medical Technologies, Inc. (NASDAQ: HSDT ) shares climbed 145.3% to close at $1.58 on Wednesday after dropping 13% on Tuesday. Kaspien Holdings Inc. (NASDAQ: KSPN ) jumped 140.3% to close at $6.20. Enveric Biosciences, Inc. (NASDAQ: ENVB ) gained 106% to settle at $13.10. Enveric Biosciences recently announced an $8 million registered direct offering and private placement. Heart Test Laboratories, Inc. (NASDAQ: HSCS ) jumped 89.6% to close at $3.28. Poseida Therapeutics, Inc. (NASDAQ: PSTX ) shares surged 85.6% to close at $4.51 as the company entered into a strategic collaboration and license agreement with Roche Holdings AG, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. Eargo, Inc. (NASDAQ: EAR ) shares gained 75.6% to settle at $1.23.
→ Google 번역
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT ) shares jumped 167% to $1.72 after dropping 13% on Tuesday. Kaspien Holdings Inc. (NASDAQ: KSPN ) gained 112.4% to $5.48. Eargo, Inc. (NASDAQ: EAR ) shares climbed 102.8% to $1.42. The company is scheduled to report Q2 earnings on Monday, August 8. Poseida Therapeutics, Inc. (NASDAQ: PSTX ) shares jumped 99.6% to $4.85 as the company entered into a strategic collaboration and license agreement with Roche Holdings AG, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. Applied DNA Sciences, Inc. (NASDAQ: APDN ) climbed 75.7% to $4.92 on continued strength after the company initiated analytical validation of a Company-developed, PCR-based monkeypox virus test that is specific for the genetic signature of the monkeypox virus. Kintara Therapeutics, Inc. (NASDAQ: KTRA ) gained 70% to $0.3013 after the company entered into an equity purchase agreement with Lincoln Park Capital for up to $20 million. Ping Identity Holding Corp. (NYSE: PING ) shares climbed 59.8% to $27.92 after the company announced it will be acquired by Thoma Bravo for $28.50 per share in cash.
→ Google 번역
NeuroOne Medical Technologies (NMTC) entered into an amendment to its Exclusive Development and Distribution Agreement with Zimmer Biomet (ZBH) providing the company with a…
→ Google 번역
https://www.investing.com/news/pro/zimmer-biomet-pt-raised-to-135-at-stifel-432SI-2861045
→ Google 번역
https://www.investing.com/news/pro/zimmer-biomet-pt-raised-to-119-at-citi-432SI-2860908
→ Google 번역
Zimmer Biomet (ZBH) stock gained as much as 6.1% to $116.46 in Tuesday trading, after the medical device company reported Q2 results that beat estimates and raised its FY 2022…
→ Google 번역
The global biosurgery market size was USD 12.4 Bn in 2021 and is anticipated to reach USD 21.2 Bn in 2031, growing at a rate [read full press release…]
→ Google 번역
Companies Reporting Before The Bell • Ferrari (NYSE: RACE ) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion. • AudioCodes (NASDAQ: AUDC ) is estimated to report quarterly earnings at $0.34 per share on revenue of $68.33 million. • Kopin (NASDAQ: KOPN ) is estimated to report quarterly loss at $0.03 per share on revenue of $12.56 million. • Rhythm Pharmaceuticals (NASDAQ: RYTM ) is expected to report quarterly loss at $0.95 per share on revenue of $2.58 million. • Eos Energy Enterprises (NASDAQ: EOSE ) is projected to report quarterly loss at $0.59 per share on revenue of $6.61 million. • Sprott (NYSE: SII ) is estimated to report earnings for its second quarter. • Element Solutions (NYSE: ESI ) is likely to report quarterly loss at $0.15 per share on revenue of $321.97 million. • GEO Group (NYSE: GEO ) is estimated to report quarterly earnings at $0.31 per share on revenue of $561.50 million. • Blueprint Medicines (NASDAQ: BPMC ) is expected to report quarterly loss at $2.
→ Google 번역
Related Stocks: FISV , ZBH , JPM , LOW , LHX ,
→ Google 번역
Zimmer Biomet (ZBH) is scheduled to announce Q2 earnings results on Tuesday, August 2nd, before market open.The consensus EPS Estimate is $1.64 (-13.7% Y/Y) and the consensus…
→ Google 번역
This Global Autotransfusion Devices Market assessment by insightSLICE evaluates past and present economic prospects and trends for the years 2022 to 2032 to provide significant insight into key market drivers. There is wide acceptance of Autotransfusion Devices across the buyers''
→ Google 번역
The global biosurgery market size was USD 12.4 Bn in 2021 and is anticipated to reach USD 21.2 Bn in 2031, growing at a rate of 5.5% from 2022 to 2031. Global Biosurgery Market report from Global Insight Services is the
→ Google 번역
Zimmer Biomet (ZBH) and the Hospital for Special Surgery will form the HSS/Zimmer Biomet Innovation Center for Artificial Intelligence in Robotic Joint Replacement.
→ Google 번역
Some of the major players operating in the craniomaxillofacial devices industry are Johnson & Johnson, Stryker Corporation, Medtronic, Aesculap Implants Systems (B Braun Melsungen AG), and Zimmer Biomet. SELBYVILLE, Del., July 20, 2022 /PRNewswire/ -- The craniomaxillofacial devices market value is expected to reach USD 3 billion by 2030, according to a new research report by Global Market
→ Google 번역
Zimmer Biomet Holdings found using ticker (ZBH) have now 19 analysts covering the stock. The analyst consensus points to a rating of ''Hold''. The target price ranges between 145 and 114 calculating the mean target price we have 128.58. With the stocks previous close at 101.65 this indicates there is a potential upside of 26.5%. The 50 day MA is 112.3 and the 200 moving average now moves to 122.69. The market cap for the company is $21,693m. Visit the company website at: https://www.zimmerbiomet.com [stock_market_widget type="chart" template="basic" color="green" assets="ZBH" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $27,440m based on the market concensus. Zimmer Biomet Holdings, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
→ Google 번역
The ZIMMER FOR SENATE INC successfully filed their F3N JULY QUARTERLY with the coverage period of 04/01/2022 to 06/30/2022 and a confirmation ID of FEC-1608448 *********CommitteeId: C00449074 | FilingId: 1608448 | FormType: F3N | CoverageFrom: 04/01/2022 | CoverageThrough: 06/30/2022 | ReportType: JULY QUARTERLY*********
→ Google 번역
ZimVie was spun out of Zimmer Biomet in March. See why we recommended investors to look for opportunities to accumulate ZIMV stock in the coming months.
→ Google 번역
WARSAW, Ind., July 5, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Tuesday, August 2, 2022 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that…
→ Google 번역
Zimmer Biomet Holdings Inc (ZBH) shares closed today at 0.4% above its 52 week low of $102.22, giving the company a market cap of $21B. The stock is currently down 19.0% year-to-date, down 35.7% over the past 12 months, and down 15.5% over the past five years. This week, the Dow Jones Industrial Average fell 4.8%, and the S&P 500 fell 5.7%. Trading Activity Trading volume this week was 17.3% higher than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 2.8% lower than its 5-day moving average, 11.2% lower than its 20-day moving average, and 15.2% lower than its 90-day moving average.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -28.6% The company's stock price performance over the past 12 months lags the peer average by 35.7% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 183.8% higher than the average peer.
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
→ Google 번역
Pune, June 13, 2022 (GLOBE NEWSWIRE) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Global " Medical Supplies Market " is a comprehensive research that provides information regarding Medical Supplies market size, trends, growth, cost structure, capacity, revenue, and forecast for 2028. This report also includes the overall study of the Medical Supplies Market share with all its aspects influencing the growth of the market. This report is exhaustive quantitative analyses of the Medical Supplies industry and provides data for making strategies to increase Medical Supplies market growth and effectiveness. The report further investigates and assesses the current landscape of the ever-evolving business sector and the present and future effects of COVID-19 on the Medical Supplies market. The report provides key statistics on the market status of the Medical Supplies manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.
→ Google 번역
Zimmer Biomet Holdings with ticker code (ZBH) now have 19 analysts covering the stock. The analyst consensus points to a rating of ''Hold''. The range between the high target price and low target price is between 145 and 114 and has a mean target at 130.95. With the stocks previous close at 115.03 this would indicate that there is a potential upside of 13.8%. The 50 day moving average now sits at 122.12 and the 200 day moving average is 127.03. The market capitalisation for the company is $23,762m. Company Website: https://www.zimmerbiomet.com [stock_market_widget type="chart" template="basic" color="green" assets="ZBH" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $27,050m based on the market concensus. Zimmer Biomet Holdings, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
→ Google 번역
The Joint Replacement global market is thoroughly researched in this report, noting important aspects like market competition, global and regional growth, market segmentation and market structure. The report author analysts have estimated the size of the global market in terms
→ Google 번역
Prince George-Peace River-Northern Rockies MP, who has long lobbied against stricter firearms legislation, is slamming the last restrictions proposed by Ottawa. Zimmer, who is also co-chair of the Parliamentary Outdoor Caucus, says the new regulations show a lack of respect for the country’s outdoor community. The legislation, tabled earlier this week, include a national freeze […]
→ Google 번역
Zimmer Biomet Holdings found using ticker (ZBH) now have 20 analysts in total covering the stock. The consensus rating is ''Hold''. The range between the high target price and low target price is between 145 and 114 calculating the average target price we see 131.55. With the stocks previous close at 120.65 this would imply there is a potential upside of 9.0%. There is a 50 day moving average of 123.11 and the 200 moving average now moves to 128.1. The company has a market capitalisation of $25,114m. Find out more information at: https://www.zimmerbiomet.com [stock_market_widget type="chart" template="basic" color="green" assets="ZBH" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $27,382m based on the market concensus. Zimmer Biomet Holdings, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.
→ Google 번역
Needham downgraded Zimmer Biomet (ZBH) to Hold from Buy, projecting Warsaw, Indiana-based maker of musculoskeletal reconstruction products to lag peers in terms of revenue and…
→ Google 번역
New York, United States, May 27, 2022 (GLOBE NEWSWIRE) -- Surgical robots are regarded as the highly advanced technological robots that allows the surgeons to perform surgeries in the human body through small incisions. The surgical robots also allow the surgeons to perform different types of complex surgical operations with more flexibility, precision, and control as compared to the conventional techniques. In terms of End-User, the Hospital segment accounted for the highest share of around 71.22% in 2020 & in terms of region, North America led the market with a share of around 67.98%. However, the Asia-Pacific region witnessed the fastest market growth rate, with a promising CAGR of around 23.32%. To get a first-hand overview of the report, Request a Sample at https://www.strategicmarketresearch.com/request-sample/surgical-robots-market The report broadcasted by Strategic Market Research on Surgical Robots Market is ramified based on: Application Orthopedics Neurology Urology Gynaecology General Surgery Others End-User Hospitals Ambulatory Surgical Centres Others Regions: North America USA Mexico Canada Rest of North America Europe Germany France Russia Switzerland U.K Finland Turkey Netherlands Belgium Spain Italy Rest of Europe Asia Pacific China India Indonesia Thailand Japan South Korea Singapore Malaysia Philippines Australia New Zealand Rest of APAC LAMEA Brazil Saudi Arabia Uruguay Argentina Rest of LAMEA Make a Direct Purchase of the latest Surgical Robots Market Report published in the month of April 2022.
→ Google 번역
Within the last quarter, Zimmer Biomet Holdings (NYSE: ZBH ) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 3 0 0 Last 30D 0 0 0 0 0 1M Ago 0 1 2 0 0 2M Ago 0 0 0 0 0 3M Ago 1 0 1 0 0 In the last 3 months, 5 analysts have offered 12-month price targets for Zimmer Biomet Holdings. The company has an average price target of $135.6 with a high of $155.00 and a low of $125.00. Below is a summary of how these 5 analysts rated Zimmer Biomet Holdings over … Full story available on Benzinga.com
→ Google 번역
Major players in the spine implants market are Medtronic, Depuy Synthes, Johnson & Johnson, Stryker Corporation, NuVasive, Inc. , Zimmer Biomet Holdings, Globus Medical, Alphatec Holdings, Orthofix International, and RTI Surgical. Major players in the spine implants market are Medtronic, Depuy Synthes, Johnson & Johnson, Stryker Corporation, NuVasive, Inc. , Zimmer Biomet Holdings, Globus Medical, Alphatec Holdings, Orthofix International, and RTI Surgical.
→ Google 번역
Major players in the implantable biomaterials market are Evonik Industries AG, Royal DSM, Zimmer Biomet Holdings, Carpenter Technology Corporation, Collagen Matrix, Corbion, BASF SE, Invibio Ltd. , and Celanese Corporation. Major players in the implantable biomaterials market are Evonik Industries AG, Royal DSM, Zimmer Biomet Holdings, Carpenter Technology Corporation, Collagen Matrix, Corbion, BASF SE, Invibio Ltd. , and Celanese Corporation.
→ Google 번역
Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ: KNSA ) is projected to report earnings for its first quarter. • Great Lakes Dredge & Dock (NASDAQ: GLDD ) is likely to report quarterly earnings at $0.16 per share on revenue of $170.53 million. • Enel Chile (NYSE: ENIC ) is expected to report quarterly earnings at $82.88 per share on revenue of $994.35 million. • Paramount Global (NASDAQ: PARAA ) is likely to report quarterly earnings at $0.52 per share on revenue of $7.38 billion. • Triton International (NYSE: TRTN ) is likely to report quarterly earnings at $2.63 per share on revenue of $419.07 million. • Colliers Intl Gr (NASDAQ: CIGI ) is likely to report quarterly earnings at $1.59 per share on revenue of $1.14 billion. • Comstock Mining (AMEX: LODE ) is projected to report quarterly loss at $0.03 per share on revenue of $380.00 thousand. • GEO Group (NYSE: GEO ) is expected to report quarterly earnings at $0.22 per share on revenue of $551.47 million. • Kopin (NASDAQ: KOPN ) is expected to report quarterly loss at $0.
→ Google 번역
This report studies the Orthopedic Bone Cement Material Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Orthopedic Bone Cement Material market segmented []
→ Google 번역
This report studies the Neurosurgery Surgical Power Tool Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Neurosurgery Surgical Power Tool market segmented []
→ Google 번역
This report studies the Bone Graft and Substitute Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Bone Graft and Substitute market segmented []
→ Google 번역